Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA

The Molecular Imaging Branch (MIB) is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. The use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. • The MIB conducts research in designing, developing, and testing new novel targeted imaging agents for the detection and characterization of cancer. • The MIB is focused on the clinical translation of targeted imaging and therapy agents for improving cancer therapy. • The B-hIL2RA transgenic mouse strain has proven invaluable in the MIB's ongoing research program.